A physician-grade research console for the semaglutide evidence base — GLP-1 receptor pharmacology, the STEP and SELECT programs, and exactly what each trial measured, with the source attached.
Semaglutide Dr.

Semaglutide Dosage: Studied Protocols and Titration Data

Dosing Frameworks Across the Trial Program

Semaglutide clinical trials used three distinct dosing frameworks depending on indication and formulation. Each is described here as documented in the trial protocol; this is not prescribing guidance.

FDA-approved indications and their labeled dose ranges are documented in this section. Semaglutide is a prescription medication; all dosing decisions are made by prescribers, not by this site.

Semaglutide Dosing Protocols in Clinical Trials

The STEP program obesity titration schedule, as documented in the trial protocol and FDA label for chronic weight management [1][15]:

  • Weeks 1-4: 0.25 mg subcutaneous once weekly
  • Weeks 5-8: 0.5 mg subcutaneous once weekly
  • Weeks 9-12: 1.0 mg subcutaneous once weekly
  • Weeks 13-16: 1.7 mg subcutaneous once weekly
  • Week 17 onward (maintenance): 2.4 mg subcutaneous once weekly

The slow 16-week escalation was designed to minimize gastrointestinal adverse events during initiation. STEP trial data show GI side effects were highest during dose escalation (weeks 1-20) and declined as participants reached maintenance dosing [12].

The SUSTAIN program type 2 diabetes dosing [6][22]:

  • Weeks 1-4: 0.25 mg subcutaneous once weekly (initiation dose; not therapeutically effective for glycemic control but tolerability-established)
  • Weeks 5 onward: 0.5 mg maintenance; escalate to 1.0 mg if additional glycemic control needed
  • SUSTAIN FORTE protocol extended to 2.0 mg as a higher-dose option; 2.0 mg produced greater HbA1c reduction (−2.2%) versus 1.0 mg (−1.9%) and more weight loss (−6.9 kg versus −6.0 kg) in 961 patients over 40 weeks [22]

The PIONEER program oral semaglutide dosing [23]:

  • Initiation: 3 mg oral daily for 4 weeks
  • Dose 2: 7 mg oral daily for 4 weeks or longer
  • Maintenance: 14 mg oral daily (the only dose with full efficacy data; PIONEER 1 showed HbA1c reductions of −1.4 to −1.5% with 7 mg and 14 mg versus −0.1% placebo)
  • Administration: taken 30 minutes before the first meal of the day, with water only; food, other liquids, or other oral medications taken within 30 minutes reduce absorption via SNAC competition [8][23]

Semaglutide Half-Life and Duration of Action

Plasma half-life: approximately 145-168 hours across studied populations, with a mean of approximately 165 hours [8]. The extended half-life is achieved via the C18 fatty-diacid side chain, which confers greater than 99% albumin binding at therapeutic concentrations and protects the molecule from DPP-4 enzymatic degradation and renal filtration.

Subcutaneous Tmax (time to peak plasma concentration): 24-72 hours after injection [8]. Bioavailability of the subcutaneous formulation: approximately 89%.

Time to full clearance after the final dose: approximately 5 weeks (5 × half-life = approximately 825 hours, or 34 days) [8]. This extended clearance window is clinically relevant: effects on appetite, gastric emptying, and glucose regulation persist for 4-5 weeks after the last injection.

Renal or hepatic impairment does not require dose adjustment based on pharmacokinetic data — semaglutide is primarily eliminated via proteolytic degradation rather than renal or hepatic clearance pathways, and neither impairment significantly alters exposure in the studies reviewed [8].

How Long Does Semaglutide Stay in Your System?

Plasma half-life is approximately 165-168 hours (approximately 7 days), enabling once-weekly dosing with stable trough concentrations at steady state [8]. Steady state is reached after 4-5 weekly doses — consistent with the 16-week titration schedule in STEP trials, which reaches maintenance dose approximately when steady-state pharmacokinetics are established.

After the final dose, detectable drug levels persist for approximately 5 weeks. The pharmacokinetic review by Yang and Yang (2024) across 16+ studies confirms clearance rate 0.030-0.047 L/h, volume of distribution approximately 12.5 L [8].

Reconstitution Protocols in Published Research

Research literature on lyophilized (compounded) semaglutide preparations documents reconstitution with bacteriostatic water. Standard research concentrations described: 5 mg/mL (1 mL added to a 5 mg vial) or 5 mg/mL (2 mL added to a 10 mg vial) [13]. The specific volume added determines the working concentration, and researchers state the volume on the vial or in the protocol documentation.

This site documents research methods. The FDA removed semaglutide from the drug shortage list in February 2025, closing the shortage-pathway authorization for 503A pharmacy compounding after April 22, 2025, and for 503B outsourcing facilities after May 22, 2025 [13]. Compounding pathways available during the shortage period are no longer authorized under the shortage exemption. This is a regulatory finding, not clinical guidance.

Commercial pre-filled pens used in clinical trials are documented as stable at room temperature up to 30°C for up to 56 days after first use. Reconstituted research preparations were typically stored at 2-8°C and used within 28 days in research protocols.